Literature DB >> 22008914

Evaluation of residual promoter activity in γ-retroviral self-inactivating (SIN) vectors.

Wenqin Xu1, Jill L Russ, Maribeth V Eiden.   

Abstract

Therapeutic gene delivery mediated by retroviral vectors has the advantage of stable integration into the host genome. A major safety concern for gene delivery achieved by murine leukemia virus (MLV)-based retroviral vectors is the activation of adjacent cellular genes including oncogenes following integration into the host genome. Self-inactivating (SIN) vectors lacking viral enhancers/promoters in their 3' long terminal repeat (LTR) have been proposed as a means of overcoming this safety concern. However the MLV-based SIN vectors currently used by laboratories to assess insertional mutagenesis, integration site selection, and the potency of transgene expression are not uniform in the composition of their 3' LTRs. We constructed a series of SIN vectors representative of the currently employed vectors, but lacking an internal promoter. Green fluorescent protein (GFP) was used as a reporter gene. Target cells exposed to these vectors were evaluated for number of integrants and GFP expression at the messenger RNA (mRNA) level and protein level. We found that viral promoter activity in the 3' LTR is not attenuated in many currently employed SIN vectors. These results suggest that the influence of strong residual promoter activity should be taken into consideration when interpreting experimental results obtained using SIN vectors in gene therapy research.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22008914      PMCID: PMC3255602          DOI: 10.1038/mt.2011.204

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  33 in total

1.  Q vectors, bicistronic retroviral vectors for gene transfer.

Authors:  M A Julius; Q Yan; Z Zheng; J Kitajewski
Journal:  Biotechniques       Date:  2000-04       Impact factor: 1.993

2.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Christof von Kalle; Manfred Schmidt; Françoise Le Deist; Nicolas Wulffraat; Elisabeth McIntyre; Isabelle Radford; Jean-Luc Villeval; Christopher C Fraser; Marina Cavazzana-Calvo; Alain Fischer
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

3.  Gene therapy of X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Genevieve de Saint Basile; Marina Cavazzana-Calvo
Journal:  Methods Mol Biol       Date:  2003

4.  Self-inactivating retroviral vectors with improved RNA processing.

Authors:  J Kraunus; D H S Schaumann; J Meyer; U Modlich; B Fehse; G Brandenburg; D von Laer; H Klump; A Schambach; J Bohne; C Baum
Journal:  Gene Ther       Date:  2004-11       Impact factor: 5.250

5.  Non-function of a Moloney murine leukaemia virus regulatory sequence in F9 embryonal carcinoma cells.

Authors:  E Linney; B Davis; J Overhauser; E Chao; H Fan
Journal:  Nature       Date:  1984 Mar 29-Apr 4       Impact factor: 49.962

6.  Construction of retroviral vectors with enhanced efficiency of transgene expression.

Authors:  Sung Ho Hahm; Youngsuk Yi; Dug Keun Lee; Moon Jong Noh; Lillian Yun; Sally Hwang; Kwan Hee Lee
Journal:  J Virol Methods       Date:  2004-11       Impact factor: 2.014

7.  LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.

Authors:  S Hacein-Bey-Abina; C Von Kalle; M Schmidt; M P McCormack; N Wulffraat; P Leboulch; A Lim; C S Osborne; R Pawliuk; E Morillon; R Sorensen; A Forster; P Fraser; J I Cohen; G de Saint Basile; I Alexander; U Wintergerst; T Frebourg; A Aurias; D Stoppa-Lyonnet; S Romana; I Radford-Weiss; F Gross; F Valensi; E Delabesse; E Macintyre; F Sigaux; J Soulier; L E Leiva; M Wissler; C Prinz; T H Rabbitts; F Le Deist; A Fischer; M Cavazzana-Calvo
Journal:  Science       Date:  2003-10-17       Impact factor: 47.728

8.  Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.

Authors:  Salima Hacein-Bey-Abina; Alexandrine Garrigue; Gary P Wang; Jean Soulier; Annick Lim; Estelle Morillon; Emmanuelle Clappier; Laure Caccavelli; Eric Delabesse; Kheira Beldjord; Vahid Asnafi; Elizabeth MacIntyre; Liliane Dal Cortivo; Isabelle Radford; Nicole Brousse; François Sigaux; Despina Moshous; Julia Hauer; Arndt Borkhardt; Bernd H Belohradsky; Uwe Wintergerst; Maria C Velez; Lily Leiva; Ricardo Sorensen; Nicolas Wulffraat; Stéphane Blanche; Frederic D Bushman; Alain Fischer; Marina Cavazzana-Calvo
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

9.  A Mus dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ectropic, amphotropic, xenotropic, and mink cell focus-forming viruses.

Authors:  M R Lander; S K Chattopadhyay
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

10.  Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency.

Authors:  Susannah I Thornhill; Axel Schambach; Steven J Howe; Meera Ulaganathan; Elke Grassman; David Williams; Bernhard Schiedlmeier; Neil J Sebire; H Bobby Gaspar; Christine Kinnon; Christopher Baum; Adrian J Thrasher
Journal:  Mol Ther       Date:  2008-01-08       Impact factor: 11.454

View more
  15 in total

Review 1.  Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy.

Authors:  Dayananda Kasala; A-Rum Yoon; Jinwoo Hong; Sung Wan Kim; Chae-Ok Yun
Journal:  Nanomedicine (Lond)       Date:  2016-06-27       Impact factor: 5.307

2.  A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells.

Authors:  Sriram Vijayraghavan; Boris Kantor
Journal:  J Vis Exp       Date:  2017-12-12       Impact factor: 1.355

3.  Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9.

Authors:  Calvin J Stephens; Elvin J Lauron; Elena Kashentseva; Zhi Hong Lu; Wayne M Yokoyama; David T Curiel
Journal:  J Control Release       Date:  2019-02-13       Impact factor: 9.776

4.  Restricted transgene expression in the brain with cell-type specific neuronal promoters.

Authors:  Aurélie Delzor; Noelle Dufour; Fanny Petit; Martine Guillermier; Diane Houitte; Gwennaelle Auregan; Emmanuel Brouillet; Philippe Hantraye; Nicole Déglon
Journal:  Hum Gene Ther Methods       Date:  2012-08-30       Impact factor: 2.396

5.  The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblastic leukemia.

Authors:  Haiqing Ma; Saradhi Mallampati; Yue Lu; Baohua Sun; Enze Wang; Xiaohong Leng; Yun Gong; Haifa Shen; C Cameron Yin; Dan Jones; Hesham M Amin; M James You; Patrick Zweidler-McKay; Yupo Ma; Hagop M Kantarjian; Ralph B Arlinghaus; Armand Glassman; Xiaoping Sun
Journal:  Haematologica       Date:  2014-07-04       Impact factor: 9.941

6.  Transduction of fetal mice with a feline lentiviral vector induces liver tumors which exhibit an E2F activation signature.

Authors:  Reba Condiotti; Daniel Goldenberg; Hilla Giladi; Temima Schnitzer-Perlman; Simon N Waddington; Suzanne Mk Buckley; Denise Heim; Wing Cheung; Matthew Themis; Charles Coutelle; Alina Simerzin; Emma Osejindu; Henning Wege; Michael Themis; Eithan Galun
Journal:  Mol Ther       Date:  2013-08-28       Impact factor: 11.454

7.  Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application.

Authors:  Ling Zhang; Steven A Feldman; Zhili Zheng; Nachimuthu Chinnasamy; Hui Xu; Azam V Nahvi; Mark E Dudley; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunother       Date:  2012-06       Impact factor: 4.456

8.  Simple viral/minimal piggyBac hybrid vectors for stable production of self-inactivating gamma-retroviruses.

Authors:  Boris Troyanovsky; Vira Bitko; Brian Fouty; Victor Solodushko
Journal:  BMC Res Notes       Date:  2015-08-27

Review 9.  Alpharetroviral vectors: from a cancer-causing agent to a useful tool for human gene therapy.

Authors:  Julia D Suerth; Verena Labenski; Axel Schambach
Journal:  Viruses       Date:  2014-12-05       Impact factor: 5.048

Review 10.  Progresses towards safe and efficient gene therapy vectors.

Authors:  Sergiu Chira; Carlo S Jackson; Iulian Oprea; Ferhat Ozturk; Michael S Pepper; Iulia Diaconu; Cornelia Braicu; Lajos-Zsolt Raduly; George A Calin; Ioana Berindan-Neagoe
Journal:  Oncotarget       Date:  2015-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.